공시 • Sep 18
HLB Co., Ltd. (KOSDAQ:A028300) agreed to acquire HLB SCIENCE Inc. (XKON:A343090) from HLB GLOBAL Co., Ltd. (KOSE:A003580), HLB bioStep Co.,Ltd. (KOSDAQ:A278650), HLB Life Science Co., Ltd. (KOSDAQ:A067630), Yoon Jong-seon and others for KRW 30.9 billion. HLB Co., Ltd. (KOSDAQ:A028300) agreed to acquire HLB SCIENCE Inc. (XKON:A343090) from HLB GLOBAL Co., Ltd. (KOSE:A003580), HLB bioStep Co.,Ltd. (KOSDAQ:A278650), HLB Life Science Co., Ltd. (KOSDAQ:A067630), Yoon Jong-seon and others for KRW 30.9 billion on September 17, 2025. HLB Co., Ltd and HLB SCIENCE Inc will enter into an agreement on September 17, 2025. HLB Co., Ltd. entered into merger agreement to acquire HLB SCIENCE Inc. from HLB GLOBAL Co., Ltd., HLB bioStep Co.,Ltd., HLB Life Science Co., Ltd., Yoon Jong-seon and others on September 18, 2025. The consideration consists of 0.8 million common equity of HLB Co., Ltd. at a ratio of 0.044632 per common equity of HLB SCIENCE Inc. As part of consideration, an undisclosed value is paid towards common equity of HLB SCIENCE Inc. After the completion of this merger, Jin Yang-gon's stake in HLB Co., Ltd., is expected to change from 7.22% to 7.18%.
The approvals of board of directors and general shareholders' meeting of HLB Co., Ltd. and HLB SCIENCE Inc., all requirements required under relevant laws and regulations of the Republic of Korea. The transaction is expected to close on January 1, 2026. New Risk • Aug 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩30.8b market cap, or US$22.2m). New Risk • Jul 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (₩28.1b market cap, or US$20.4m). 공시 • Mar 07
HLB SCIENCE Inc., Annual General Meeting, Mar 25, 2025 HLB SCIENCE Inc., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 66, achasan-ro, seongdong-gu, seoul South Korea New Risk • Mar 12
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩41.4b market cap, or US$31.7m). New Risk • Oct 19
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 50% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (50% increase in shares outstanding). Market cap is less than US$100m (₩28.6b market cap, or US$21.1m). 공시 • Feb 02
HLB SCIENCE Inc. announced that it expects to receive KRW 5.0000004 billion in funding from KNOTUS Co.,Ltd HLB SCIENCE Inc. announced a private placement of series 4 unsecured privately placed convertible bonds with bearer interest for the gross proceeds of KRW 2,000,000,000 on February 1, 2023. The transaction will include participation from KNOTUS Co.,Ltd. The bonds carry a coupon rate of 2% and yield to maturity rate of 2% and will mature on February 9, 2028. The series 4 bonds are fully convertible into 782,778 common shares at a conversion price of KRW 2,555 per share from February 9, 2024 to January 9, 2028. The bonds are restricted to a hold period of 1 year from the date of issuance. The transaction has been approved by shareholders of the company. The transaction is expected to close on February 9, 2023.
On the same date, the company announced a private placement of 1,304,348 common shares at an issue price of KRW 2,300 per share for gross proceeds of KRW 3,000,000,400. The transaction will include participation from KNOTUS Co.,Ltd for 1,304,348 shares. The shares are restricted to a hold period of one year. The method of capital is through third party allocation increase. The transaction has been approved by shareholders of the company. The transaction is expected to close on February 9, 2023. 공시 • Jun 16
DandiBioscience, Inc. announced that it expects to receive KRW 8.4 billion in funding DandiBioscience, Inc. (XKON:A343090) announced that it will issue round 3 non-guaranteed private equity convertible bonds with bearer food vouchers for gross proceeds of KRW 8,400,000,000 on June 15, 2021. The transaction will include participation from 21-07 Cyclamen New Technology Association No. 38-Eastgate Investment Co. , Ltd. for 2,000,000,000, Green Marine No. 1 Fund for 4,000,000,000, Jihoon Park for 2,000,000,000, Dong-ho Dong for 100,000,000, along with executives In-deok Jeong and Yong-joo Kim and Young-min Park for 50,000,000 each. The transaction will also include participation from Won-jin Kwon, Jin-wook Baek and Ji-won Kang for 50,000,000 each. The bonds will be issued at par. The bonds carry a coupon rate of 1% with a yield to maturity of 2% per annum. The bonds will mature on July 07, 2024. The bonds are convertible into 957,041 common shares of the company at a fixed conversion price of KRW 8,777 per share from July 07, 2022 to June 07, 2024. The date of subscription is June 17, 2021 and expected date of payment is July 07, 2021. The transaction is approved by the board of directors of the company. The bonds are subject to prohibition of conversion and division of rights for one year from the date of issue of bonds. 공시 • Apr 24
DandiBioscience, Inc. announced that it has received KRW 1.3 billion in funding On April 22, 2021, DandiBioscience, Inc. (XKON:A343090) closed the transaction. 공시 • Mar 04
DandiBioscience, Inc., Annual General Meeting, Mar 25, 2021 DandiBioscience, Inc., Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time. Is New 90 Day High Low • Feb 23
New 90-day low: ₩4,900 The company is down 24% from its price of ₩6,470 on 25 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Feb 04
New 90-day low: ₩5,500 The company is down 21% from its price of ₩6,980 on 05 November 2020. The South Korean market is up 28% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 20% over the same period. Is New 90 Day High Low • Jan 06
New 90-day low: ₩6,100 The company is down 2.0% from its price of ₩6,220 on 08 October 2020. The South Korean market is up 24% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 23% over the same period. Is New 90 Day High Low • Nov 02
New 90-day high: ₩6,650 The company is up 29% from its price of ₩5,150 on 04 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 11% over the same period. Is New 90 Day High Low • Oct 15
New 90-day high: ₩6,440 The company is up 20% from its price of ₩5,380 on 17 July 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 3.0% over the same period. 